|  | | RMST at times (years) | | | | Survival proportions at times (years) | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Source | 4 | 8 | 15 | 50\* | 4 | 8 | 15 | 50\* |
| **FC** | **Observed** | **3.56** | **5.99** |  |  | **0.77** | **0.41** |  |  |
|  | Semi-Markov: SPMs, ASF (Williams et al.) | 3.53 | 5.61 | 6.87 | 7.08 | 0.73 | 0.34 | 0.08 | 0.00 |
|  | Semi-Markov: FPMs, ASF | 3.51 | 5.86 | 8.16 | 11.66 | 0.72 | 0.45 | 0.25 | 0.04 |
|  | Semi-Markov: FPMs, RSF (Proposed method) | 3.52 | 5.86 | 8.08 | 10.06 | 0.72 | 0.45 | 0.23 | 0.00 |
|  | Markov: SPMs, ASF | 3.18 | 4.66 | 6.65 | 16.51 | 0.54 | 0.29 | 0.28 | 0.28 |
|  | Markov: FPMs, ASF | 3.53 | 6.57 | 11.19 | 30.34 | 0.79 | 0.70 | 0.63 | 0.50 |
|  | Markov: FPMs, RSF | 3.54 | 6.57 | 10.95 | 18.54 | 0.80 | 0.69 | 0.57 | 0.00 |
| **RFC** | **Observed** | **3.68** | **6.54** |  |  | **0.84** | **0.61** |  |  |
|  | Semi-Markov: SPMs, ASF (Williams et al.) | 3.63 | 5.80 | 6.85 | 6.97 | 0.77 | 0.33 | 0.05 | 0.00 |
|  | Semi-Markov: FPMs, ASF | 3.62 | 6.12 | 8.24 | 10.39 | 0.77 | 0.47 | 0.20 | 0.01 |
|  | Semi-Markov: FPMs, RSF (Proposed method) | 3.62 | 6.12 | 8.17 | 9.55 | 0.77 | 0.46 | 0.18 | 0.00 |
|  | Markov: SPMs, ASF | 3.40 | 4.99 | 6.60 | 14.53 | 0.63 | 0.25 | 0.23 | 0.23 |
|  | Markov: FPMs, ASF | 3.66 | 6.89 | 11.70 | 30.94 | 0.84 | 0.74 | 0.65 | 0.49 |
|  | Markov: FPMs, RSF | 3.66 | 6.87 | 11.46 | 19.22 | 0.84 | 0.73 | 0.59 | 0.00 |
| \*If survival proportion at 50 years is zero, the reported 50-year RMST can be regarded as life expectancy. RMST, restricted mean survival time; LE, life expectancy; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; SPMs, standard parametric models; FPMs, flexible parametric models; ASF, all-cause survival framework; RSF, relative survival framework. | | | | | | | | | |